Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD). However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants, antidiabetic drugs, and iron chelators, have failed in disease-modification clinical tri...
Պահպանված է:
Հիմնական հեղինակներ: | , , , |
---|---|
Ձևաչափ: | Հոդված |
Լեզու: | անգլերեն |
Հրապարակվել է: |
Philipps-Universität Marburg
2024
|
Խորագրեր: | |
Առցանց հասանելիություն: | PDF ամբողջական տեքստ |
Ցուցիչներ: |
Ավելացրեք ցուցիչ
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!
|
Ամփոփում: | Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD).
However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants, antidiabetic drugs,
and iron chelators, have failed in disease-modification clinical trials. In this review, we summarize the cellular determinants
of mitochondrial dysfunction, including impairment of electron transport chain complex 1, increased oxidative
stress, disturbed mitochondrial quality control mechanisms, and cellular bioenergetic deficiency. In addition,
we outline mitochondrial pathways to neurodegeneration in the current context of PD pathogenesis, and review
past and current treatment strategies in an attempt to better understand why translational efforts thus far have been
unsuccessful. |
---|---|
Նյութի նկարագրություն: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
DOI: | 10.1186/s13024-023-00676-7 |